Skip to main content

Perioperative Nutrition

Nutrition is the unglamorous axis on which reconstructive outcomes actually turn. An otherwise perfectly constructed ileal-conduit bowel anastomosis leaks if the patient is hypoalbuminemic and catabolic. A urethroplasty buccal graft fails to take in a patient who stopped eating three weeks before the operation. Malnutrition is present in 20–70% of patients undergoing major abdominal surgery and is an independent predictor of SSI, anastomotic leak, wound dehiscence, and mortality.[1][2] This article covers the evidence-based perioperative nutrition pathway — screening and assessment, preoperative optimization, immunonutrition, the EN/PN hierarchy, parenteral-nutrition formulation and complications, refeeding syndrome, and the reconstructive-urology-specific considerations.

See also: Wound Healing, Frailty, ERAS, Bowel Anastomosis.

Why Nutrition Matters in GU Reconstruction​

Nutrition intersects every outcome the reconstructive urologist cares about:

  • Wound healing — protein, arginine, vitamin C, zinc, and vitamin A are specific substrates for collagen synthesis, epithelialization, and angiogenesis. Low serum albumin is the single best-characterized predictor of wound-healing failure.
  • Anastomotic integrity — hypoalbuminemia is independently associated with anastomotic leak after bowel surgery and is a driver of conduit / neobladder leak.
  • Infection resistance — immunocompetence depends on nutritional status; malnourished patients have higher SSI rates at every contamination class.
  • Graft take — BMG and bladder-mucosa grafts depend on inosculation-phase angiogenesis, which fails in the catabolic patient.
  • Functional recovery — sarcopenia and frailty (overlapping but distinct from malnutrition) drive delirium, immobility, and delayed ambulation.

The operational principle: every patient being considered for major elective reconstruction should be screened, and every screened-at-risk patient should be optimized before the index operation whenever the surgical timeline permits.

Nutritional Screening and Assessment​

Screen every surgical patient within 24–48 h of admission and at regular intervals thereafter.[5]

Validated Screening Tools​

ToolStrengthsNotes
MUST (Malnutrition Universal Screening Tool)Best overall validity in surgical cohorts (~80% sensitivity/specificity)[6]Uses BMI, weight loss, acute-illness-no-intake
NRS-2002 (Nutritional Risk Screening)Widely used; identifies ~24% at risk[6]ESPEN standard; stratifies nutritional status + disease severity
MNA-SF (Mini Nutritional Assessment — Short Form)Best discriminatory ability (AUC 0.83); identifies ~58% at risk[6]Geriatric surgical focus
GLIM (Global Leadership Initiative on Malnutrition)Consensus diagnostic framework[7]Phenotypic + etiologic criteria

Indicators of Severe Nutritional Risk[8]​

  • BMI <18.5 kg/m²
  • Unintentional weight loss >10–15% in 6 months
  • Poor appetite / intake <50% of baseline for >1 week
  • Serum albumin <3.0 g/dL (best single lab marker in the surgical patient)
  • Active inflammation / catabolic state

Albumin is an imperfect marker — it is a negative acute-phase reactant and falls in inflammation independent of nutritional status — but remains the most widely used and most prognostic lab value in the surgical literature.

Preoperative Optimization​

Fasting and Carbohydrate Loading​

Part of the ERAS pathway — see ERAS:[9][10]

  • Clear liquids permitted to 2 h before induction.
  • Solids to 6–8 h before induction.
  • Complex-carbohydrate (maltodextrin) drink the evening before + 2 h before induction in non-diabetic patients — attenuates insulin resistance and reduces LOS by 0.3–1.7 days in major abdominal surgery.

Oral Nutritional Supplementation for At-Risk Patients​

  • Target protein intake: 1.2–1.5 g/kg/day.[1][10]
  • Duration: 7–21 days preoperatively depending on severity of risk.[11]
  • Documented reduction in postoperative complications vs no supplementation.

Prehabilitation​

Combined exercise + nutrition + smoking/alcohol cessation for 4–6 weeks before major elective reconstruction. For pelvic oncology (radical cystectomy) there is RCT-level evidence of improved functional recovery; nutritional supplementation alone also improves outcomes independently.[10]

Immunonutrition​

Definition​

Enteral formulas supplemented with arginine, omega-3 fatty acids (fish oil), glutamine, and/or nucleotides to modulate the inflammatory response.[12]

Evidence in GI Cancer Surgery​

Meta-analytic outcomes:[13][14][15]

  • Infectious complications ↓ 42–48% (OR 0.52–0.58)
  • SSI ↓ (OR 0.65)
  • Anastomotic leak ↓ (OR 0.67)
  • LOS ↓ 1.5–2 days
  • Mortality — no significant effect

Benefit is seen regardless of baseline nutritional status, and the combination of perioperative (preop + postop) immunonutrition outperforms either alone (OR 0.32 for postoperative morbidity).[15][16]

Controversy​

Effect size varies by control-group choice (isocaloric standard supplement vs unsupplemented diet) and by industry sponsorship; effects are smaller when compared against an equivalent calorie/protein control.[10]

Practical Use in Urologic Reconstruction​

Immunonutrition is reasonable for 5–7 days preoperatively before radical cystectomy with urinary diversion — the operation with the most analogous biology to the GI-cancer surgery evidence base. Less clear benefit for non-bowel urologic reconstruction.

The EN / PN Hierarchy​

Preference order:[1][4]

  1. Oral nutrition / oral supplements — always first when feasible.
  2. Enteral nutrition (EN) — tube feeding via NG, nasojejunal, PEG, PEJ, or surgical jejunostomy.
  3. Parenteral nutrition (PN) — intravenous when enteral access is impossible or insufficient.

EN is preferred over PN whenever the gut works. EN maintains the gut mucosal barrier, supports immune function, reduces infection, and costs less.[4][18]

Enteral Nutrition (EN)​

Indications​

  • High nutritional risk + inadequate oral intake.
  • Functioning GI tract without contraindication to luminal nutrients.
  • Expected inadequate oral intake for >5–7 days.

Contraindications​

  • Complete bowel obstruction
  • Bowel discontinuity (unsafe to enter lumen)
  • Bowel ischemia
  • Ongoing peritonitis

Timing​

  • Initiate within 24 h of surgery when feasible.[17][18]
  • Early EN reduces mortality (6.8% → 2.4%) and complications (RR 0.53) vs delayed feeding.

Formula Selection[18]​

TypeCompositionUse
Polymeric (standard)Whole protein, intact carb, LCTNormal GI function
Semi-elemental / elementalPeptides or free amino acids, MCT-richMalabsorption, pancreatic insufficiency, recent GI surgery
Disease-specificModified for renal, hepatic, pulmonary, glycemicPer indication
Immunonutrition+ arginine, omega-3, glutamine, nucleotidesPerioperative cancer surgery

Parenteral Nutrition (PN) — TPN vs PPN​

Indications​

  • EN not feasible or insufficient to meet caloric/protein needs.
  • Major upper-GI surgery with anticipated NPO duration ≥7 days.
  • High-output enterocutaneous fistula.
  • Severe malnutrition preceding major elective reconstruction when enteral route is inadequate.

Timing​

  • ESPEN: start PN if EN is contraindicated or has been inadequate for >7 days.[3]
  • ASPEN: start PN within 3–5 days if EN is insufficient in the high-nutritional-risk patient.[17]

TPN vs PPN — Selection​

FeaturePPN (Peripheral)TPN (Central)
AccessPeripheral IVCentral line (PICC, tunneled, port)
Osmolarity limit≤900 mOsm/LNo limit
Duration7–14 days maximumWeeks to indefinite
Dextrose concentration≤10%10–25%
Caloric deliveryOften hypocaloricFull caloric requirements
Fluid volumeLarger (2.5–3 L/day)Concentrated, smaller volumes
Typical indicationBridge therapy, EN supplement, short-termLong-term, high calorie needs, fluid-restricted
Dominant complicationPhlebitis, extravasationCLABSI, catheter thrombosis

PPN patient-selection criteria:[20]

  • No fluid restriction
  • Stable electrolytes
  • Adequate renal function for fluid load
  • Not severely catabolic
  • Duration expected ≤10–14 days
  • Goal: prevent rather than correct nutritional deficit

TPN Composition​

Macronutrients[18][19][21]​

Dextrose (carbohydrate):

  • 3.4 kcal/g
  • Available 2.5–70% concentrations
  • Target 125–200 g/day (protein-sparing up to 200 g)
  • Infusion rate limit: 4–5 mg/kg/min in critically ill, 5–7 mg/kg/min in stable patients
  • Supplies 70–85% of non-protein energy

Amino acids (protein):

  • 3–20% concentration
  • 0.10–0.15 g nitrogen/kg/day basal; 0.15–0.20 g nitrogen/kg/day in hypermetabolic states
  • ≈ 1.0–1.5 g protein/kg/day in most surgical patients

Lipids:

  • 10%, 20%, 30% emulsions (1.1, 2.0, 2.9–3.0 kcal/mL)
  • Provide 30–50% of non-protein energy
  • Essential fatty acid requirement: ~200 g lipid emulsion/week
  • Soybean-oil–based (Intralipid) — high omega-6, linked to hepatobiliary complications (PNALD)
  • Newer mixed-oil formulations (SMOFlipid — soybean + MCT + olive + fish oil; Omegaven — fish oil alone) — reduced inflammation, less hepatotoxicity[18][22]

Micronutrients[18][23]​

ComponentDaily requirementNotes
Sodium1–2 mEq/kgAdjust for losses
Potassium1–2 mEq/kgMonitor closely
Calcium10–15 mEq
Magnesium8–20 mEq
Phosphorus20–40 mmolCritical for refeeding-syndrome prevention
MultivitaminsDailyAll fat- and water-soluble
Trace elementsDailyCr, Cu, Mn, Se, Zn
Vitamin KAs neededOmit if on warfarin

Formulation Types[18]​

  • Three-in-one (TNA — total nutrient admixture): dextrose + amino acids + lipid in one bag.
  • Two-in-one: dextrose + amino acids together; lipid separately.

TPN Complications​

Catheter-Related[18][19][24]​

  • CLABSI — most common serious complication.
  • Catheter-related thrombosis.
  • Exit-site infection.
  • Occlusion, mechanical damage, dislodgement.

Metabolic[18][19][25]​

ComplicationDriverManagement
HyperglycemiaExcess dextrose, insulin resistanceLimit dextrose infusion rate, insulin
HypoglycemiaAbrupt PN discontinuationTaper PN gradually — do not stop abruptly
HypertriglyceridemiaExcess lipidLimit to 1 g/kg/day, monitor trigs
Electrolyte imbalanceInadequate provision, refeedingDaily labs, adjust formulation
Refeeding syndromeRapid feeding in malnourished patientSee dedicated section
Hepatic dysfunction (PNALD)Overfeeding, soybean lipid, absent enteral feedingCyclic PN, mixed-oil / fish-oil lipid, maintain some EN
Metabolic bone diseaseLong-term PN, aluminum contaminationVitamin D, calcium, phosphorus monitoring
AzotemiaExcess protein, dehydrationAdjust amino acids for renal function

Parenteral Nutrition–Associated Liver Disease (PNALD)​

Conjugated bilirubin ≥2 mg/dL in a patient on prolonged PN, other causes excluded.[26]

  • Incidence: up to 50% of infants on long-term PN; up to 80% in low-birth-weight infants with intestinal failure; histologic changes as early as 14 days.[26][27]
  • Progression: steatosis → cholestasis → chronic hepatitis → cirrhosis → liver failure.
  • Mechanism: soybean-oil lipid (high stigmasterol, pro-inflammatory omega-6, low vitamin E), absent enteral feeding, dysbiosis, sepsis, caloric overload.[26][28]
  • Prevention and treatment:[22][27][28][29]
    • Maintain some enteral feeding whenever feasible.
    • Cyclic PN rather than continuous.
    • Avoid overfeeding.
    • Fish-oil lipid (Omegaven) or mixed-oil (SMOFlipid) — can reverse cholestasis.
    • Limit soybean-oil dose.
    • Prevent/treat line sepsis aggressively.
    • Preserve intestinal length.

Refeeding Syndrome​

Pathophysiology​

In the chronically malnourished patient, refeeding with carbohydrate triggers insulin release, which drives intracellular shift of phosphate, potassium, and magnesium. Thiamine requirement spikes.[19][30]

Clinical Manifestations​

  • Cardiac: arrhythmia, heart failure.
  • Respiratory: weakness, respiratory failure (phosphate-dependent diaphragm function).
  • Neurologic: confusion, ataxia, ophthalmoplegia — Wernicke encephalopathy from thiamine depletion.
  • Fluid overload, edema.

Diagnostic Criteria[5]​

  • Imminent: >30% phosphate drop from baseline, or phosphate ≤0.6 mmol/L within 72 h of starting nutrition.
  • Manifest: electrolyte shifts + clinical symptoms.

Risk Factors (NICE Criteria)[5]​

  • BMI <16 kg/m²
  • Unintentional weight loss >15% in 3–6 months
  • Insufficient nutritional intake for >10 days
  • Low baseline K, phosphate, or Mg
  • History of alcohol or drug use
  • Recent medications — insulin, chemotherapy, antacids, diuretics

Prevention and Treatment[19][5][31]​

Prophylactic supplementation — before and during first 10 days:

  • Thiamine 200–300 mg/day IV
  • Potassium 2–4 mmol/kg/day
  • Phosphate 0.3–0.6 mmol/kg/day
  • Magnesium 0.2–0.4 mmol/kg/day
  • Full multivitamin

Feeding approach:

  • Start at 10–20 kcal/kg/day (not goal-feed).
  • Advance slowly to target over 5–10 days.
  • Limit sodium.
  • Daily electrolyte monitoring.

Postoperative Feeding in GU Reconstruction​

Early Oral / Enteral Feeding​

ERAS principle: drinks and food on day of surgery when tolerated; regular diet once liquids are tolerated, without waiting for flatus.[3][17]

Supplemental Parenteral Nutrition (SPN)​

For patients with poor EN tolerance after major abdominal surgery:[2]

  • Early SPN (day 3) with concurrent EN reduces nosocomial infection vs late SPN (day 8).
  • Indicated when EN delivers <60% of caloric target by day 3.

Protein Focus After Discharge​

Protein delivery matters more than total calorie delivery for healing.[1]

  • Target 1.2–1.5 g/kg/day.
  • Inadequate protein intake is common in the post-discharge setting — counsel explicitly.

Reconstruction-Specific Considerations​

  • Radical cystectomy + urinary diversion: the benchmark complex GU operation for nutrition pathways — typical 30-day readmission is often nutrition-driven (failure-to-thrive, dehydration, metabolic acidosis). ERAS + alvimopan + no routine MBP is the standard.
  • Augmentation cystoplasty with bowel: monitor for chronic metabolic acidosis from urinary reabsorption through the bowel segment; supplement bicarbonate as needed.
  • Ileal-conduit bowel-segment harvest: preserve at least 20 cm terminal ileum for B12 and bile-salt absorption; monitor long-term B12.
  • Pouches and neobladders: supplementation with bicarbonate and B12 is part of routine follow-up.
  • Urethroplasty / substitution grafts: minor nutritional footprint except in malnourished patients; preoperative albumin <3.0 g/dL is a reason to delay and optimize.

Monitoring​

Baseline: CMP, CBC, triglycerides, magnesium, phosphorus, albumin, prealbumin.

Patients on PN:[18]

  • Daily labs until stable, then ≥ weekly.
  • Glucose — check as needed for glycemic control (target 140–180 mg/dL).
  • Triglycerides with lipid infusion.

Long-term PN: iron, ferritin, zinc, copper, folate, B12, vitamin D, vitamin K.

Clinical: weight, hydration status, signs of fluid overload or dehydration, catheter site, feeding tolerance.

Key Recommendations​

  1. Screen every surgical patient for malnutrition within 24–48 h of admission.[1][3]
  2. Optimize preoperatively with oral supplementation (1.2–1.5 g/kg/day protein) for 7–21 days in malnourished patients.[10][11]
  3. Carbohydrate loading in non-diabetic patients as part of ERAS.[9]
  4. Consider immunonutrition for 5–7 days before major GI/oncologic surgery — particularly radical cystectomy.[13][14][15]
  5. Use EN preferentially over PN when the gut works.[3][4]
  6. Initiate EN within 24 h of surgery when feasible.[17]
  7. Delay PN to 5–7 days postoperatively unless high nutritional risk.[3][4]
  8. Use mixed-oil or fish-oil lipid emulsions to reduce PNALD risk.[22][27]
  9. Prevent refeeding syndrome — 10–20 kcal/kg/day start, thiamine 200–300 mg, phosphate/K/Mg repletion before and during first 10 days.[5][19]
  10. Maintain some enteral feeding whenever possible to preserve gut barrier and prevent PNALD.

References​

1. Wischmeyer PE, Carli F, Evans DC, et al. "American Society for Enhanced Recovery and Perioperative Quality Initiative Joint Consensus Statement on Nutrition Screening and Therapy Within a Surgical Enhanced Recovery Pathway." Anesth Analg. 2018;126(6):1883–1895. doi:10.1213/ANE.0000000000002743

2. Gao X, Liu Y, Zhang L, et al. "Effect of Early vs Late Supplemental Parenteral Nutrition in Patients Undergoing Abdominal Surgery: A Randomized Clinical Trial." JAMA Surg. 2022;157(5):384–393. doi:10.1001/jamasurg.2022.0269

3. Weimann A, Bezmarevic M, Braga M, et al. "ESPEN Guideline on Clinical Nutrition in Surgery — Update 2025." Clin Nutr. 2025;53:222–261. doi:10.1016/j.clnu.2025.08.029

4. McClave SA, DiBaise JK, Mullin GE, Martindale RG. "ACG Clinical Guideline: Nutrition Therapy in the Adult Hospitalized Patient." Am J Gastroenterol. 2016;111(3):315–34. doi:10.1038/ajg.2016.28

5. Schuetz P, Seres D, Lobo DN, et al. "Management of Disease-Related Malnutrition for Patients Being Treated in Hospital." Lancet. 2021;398(10314):1927–1938. doi:10.1016/S0140-6736(21)01451-3

6. Petra G, Kritsotakis EI, Gouvas N, et al. "Multicentre Prospective Study on the Diagnostic and Prognostic Validity of Malnutrition Assessment Tools in Surgery." Br J Surg. 2025;112(2):znaf013. doi:10.1093/bjs/znaf013

7. Prado CM, Ford KL, Gonzalez MC, et al. "Nascent to Novel Methods to Evaluate Malnutrition and Frailty in the Surgical Patient." JPEN J Parenter Enteral Nutr. 2023;47(Suppl 1):S54–S68. doi:10.1002/jpen.2420

8. American College of Surgeons. Geriatric Surgery Verification Program Standards. ACS; 2019.

9. Irani JL, Hedrick TL, Miller TE, et al. "Clinical Practice Guidelines for Enhanced Recovery After Colon and Rectal Surgery (ASCRS/SAGES)." Dis Colon Rectum. 2023;66(1):15–40. doi:10.1097/DCR.0000000000002650

10. Irani JL, Hedrick TL, Miller TE, et al. "Clinical Practice Guidelines for Enhanced Recovery After Colon and Rectal Surgery (ASCRS/SAGES)." Surg Endosc. 2023;37(1):5–30. doi:10.1007/s00464-022-09758-x

11. Farrell MS, Bongiovanni T, Cuschieri J, et al. "Geriatric Nutrition in the Surgical Patient: AAST Clinical Consensus Document." Trauma Surg Acute Care Open. 2025;10(1):e001602. doi:10.1136/tsaco-2024-001602

12. Howes N, Atkinson C, Thomas S, Lewis SJ. "Immunonutrition for Patients Undergoing Surgery for Head and Neck Cancer." Cochrane Database Syst Rev. 2018;8:CD010954. doi:10.1002/14651858.CD010954.pub2

13. Khan A, Wong J, Riedel B, et al. "The Impact of Peri-Operative Enteral Immunonutrition on Post-Operative Complications in Gastrointestinal Cancer Surgery: A Meta-Analysis." Ann Surg Oncol. 2023;30(6):3619–3631. doi:10.1245/s10434-023-13265-1

14. Adiamah A, Skořepa P, Weimann A, Lobo DN. "The Impact of Preoperative Immune Modulating Nutrition on Outcomes in Patients Undergoing Surgery for Gastrointestinal Cancer." Ann Surg. 2019;270(2):247–256. doi:10.1097/SLA.0000000000003256

15. Ricci C, Serbassi F, Alberici L, et al. "Immunonutrition in Patients Who Underwent Major Abdominal Surgery: A Comprehensive Systematic Review and Component Network Meta-Analysis Using GRADE and CINeMA Approaches." Surgery. 2023;174(6):1401–1409. doi:10.1016/j.surg.2023.08.005

16. Braga M. "Perioperative Immunonutrition and Gut Function." Curr Opin Clin Nutr Metab Care. 2012;15(5):485–8. doi:10.1097/MCO.0b013e3283567d8f

17. McClave SA, Taylor BE, Martindale RG, et al. "Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient (SCCM / ASPEN)." JPEN J Parenter Enteral Nutr. 2016;40(2):159–211. doi:10.1177/0148607115621863

18. Lesser MNR, Lesser LI. "Nutrition Support Therapy." Am Fam Physician. 2021;104(6):580–588.

19. Cederholm T, Bosaeus I. "Malnutrition in Adults." N Engl J Med. 2024;391(2):155–165. doi:10.1056/NEJMra2212159

20. Worthington P, Balint J, Bechtold M, et al. "When Is Parenteral Nutrition Appropriate?" JPEN J Parenter Enteral Nutr. 2017;41(3):324–377. doi:10.1177/0148607117695251

21. Ziegler TR. "Parenteral Nutrition in the Critically Ill Patient." N Engl J Med. 2009;361(11):1088–97. doi:10.1056/NEJMct0806956

22. Orso G, Mandato C, Veropalumbo C, et al. "Pediatric Parenteral Nutrition-Associated Liver Disease and Cholestasis." Dig Liver Dis. 2016;48(3):215–22. doi:10.1016/j.dld.2015.11.003

23. Ayers P, Adams S, Boullata J, et al. "A.S.P.E.N. Parenteral Nutrition Safety Consensus Recommendations." JPEN J Parenter Enteral Nutr. 2014;38(3):296–333. doi:10.1177/0148607113511992

24. Mundi MS, Mohamed Elfadil O, Hurt RT, Bonnes S, Salonen BR. "Management of Long-Term Home Parenteral Nutrition." JPEN J Parenter Enteral Nutr. 2023;47(Suppl 1):S24–S34. doi:10.1002/jpen.2424

25. Btaiche IF, Khalidi N. "Metabolic Complications of Parenteral Nutrition in Adults, Part 2." Am J Health Syst Pharm. 2004;61(19):2050–7. doi:10.1093/ajhp/61.19.2050

26. Premkumar MH, Huff KA, Cooper C, et al. "Enteral Lipid Supplements for the Prevention and Treatment of Parenteral Nutrition-Associated Liver Disease in Infants." Cochrane Database Syst Rev. 2026;1:CD014353. doi:10.1002/14651858.CD014353.pub2

27. Nandivada P, Fell GL, Gura KM, Puder M. "Lipid Emulsions in the Treatment and Prevention of Parenteral Nutrition-Associated Liver Disease in Infants and Children." Am J Clin Nutr. 2016;103(2):629S–34S. doi:10.3945/ajcn.114.103986

28. Mihajlovic M, Rosseel Z, De Waele E, Vinken M. "Parenteral Nutrition-Associated Liver Injury: Clinical Relevance and Mechanistic Insights." Toxicol Sci. 2024;199(1):1–11. doi:10.1093/toxsci/kfae020

29. Burns DL, Gill BM. "Reversal of Parenteral Nutrition-Associated Liver Disease With a Fish Oil-Based Lipid Emulsion (Omegaven) in an Adult Dependent on Home Parenteral Nutrition." JPEN J Parenter Enteral Nutr. 2013;37(2):274–80. doi:10.1177/0148607112450301

30. Stanga Z, Brunner A, Leuenberger M, et al. "Nutrition in Clinical Practice — The Refeeding Syndrome: Illustrative Cases and Guidelines for Prevention and Treatment." Eur J Clin Nutr. 2008;62(6):687–94. doi:10.1038/sj.ejcn.1602854

31. Gallagher D, Parker A, Samavat H, Zelig R. "Prophylactic Supplementation of Phosphate, Magnesium, and Potassium for the Prevention of Refeeding Syndrome." Nutr Clin Pract. 2022;37(2):328–343. doi:10.1002/ncp.10786